Physician

Sarah R Goodyear, MD

According to 2025 Medicare claims, Sarah Goodyear, MD (NPI: 1891728622) practices hematology/oncology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 18960-1560.

Goodyear's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 853 traditional Medicare patients, billed 245,710 HCPCS/CPT codes, and received $4,132,881 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,626 prescription claims across 361 beneficiaries totaling $4,689,949 in drug costs, led by Revlimid (Lenalidomide). DME data shows 15 claims. Open Payments data shows 45 records totaling $1,119. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,850,056 to $4,132,881. Similarly, Part D prescription costs have moved sharply higher in recent years, from $715,572 to $4,689,949. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	825	124,637	$1,850,056
2016	845	148,740	$2,619,245
2017	895	181,857	$2,714,091
2018	891	224,699	$3,526,276
2019	832	223,803	$3,653,482
2020	767	211,811	$3,594,562
2021	756	249,207	$3,889,982
2022	753	289,288	$4,345,696
2023	781	262,099	$4,041,973
2024	853	245,710	$4,132,881

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	245	1,134	$715,572
2016	276	1,379	$1,106,231
2017	255	1,201	$1,723,036
2018	289	1,418	$2,066,574
2019	311	1,542	$2,421,824
2020	303	1,470	$2,669,680
2021	305	1,461	$3,587,563
2022	327	1,761	$4,295,735
2023	339	1,630	$4,159,748
2024	361	1,626	$4,689,949

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	34	$25,524
2016	N/R	83	$47,253
2017	N/R	49	$20,173
2018	N/R	N/R	N/R
2019	N/R	25	$3,826
2020	N/R	86	$7,497
2021	N/R	38	$2,688
2022	N/R	34	$1,674
2023	N/R	N/R	N/R
2024	N/R	15	$1,879

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	435	676	$71
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	356	579	$14
96372	Injection of drug or substance under skin or into muscle	121	519	$12
36415	Insertion of needle into vein for collection of blood sample	182	539	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	185	639	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	49	1,239	$886,819
Ibrance	Palbociclib	41	1,127	$643,755
Imbruvica	Ibrutinib	37	1,036	$578,485
Lenalidomide	Lenalidomide	29	791	$386,965
Promacta	Eltrombopag Olamine	27	810	$343,006

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	15	$1,879

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	45	$1,119	Alexion Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sarah R. Goodyear, MD?

Tedicare shows public-source Medicare data for Sarah R. Goodyear, MD (NPI 1891728622), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sarah R. Goodyear, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sarah R. Goodyear, MD?

Sarah R. Goodyear, MD is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Sarah R. Goodyear, MD have Open Payments data?

Sarah R. Goodyear, MD has 45 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.